Nasus Pharma is a Tel Aviv clinical-stage issuer whose listed-company story now runs through a powder epinephrine candidate and a cash clock that barely covers the next readout. The Food and Drug Administration cleared the investigational new drug application for NS002 in mid-September, which is a permit to run United States studies rather than a marketing approval. That clearance arrives after a fifty-person Phase Two comparison against EpiPen and after a February private placement that refilled the till. The equity trades as a small option on whether a dry powder can outrun both the autoinjector franchise and an already approved liquid nasal spray.
The March topline is the evidence the market has to work with. Median time to the accepted plasma threshold was under two minutes on the powder. The autoinjector took more than three. A larger share of subjects crossed that line in the first five minutes, and the design included a nasal allergen challenge meant to mimic a swollen airway. That is a pharmacokinetic argument rather than a field trial in anaphylaxis. ARS Pharmaceuticals already sells a liquid nasal epinephrine under the Neffy brand, so needle-free is no longer an empty category. Powder still has a plausible edge on onset and shelf life, but that edge has to survive a larger, regulator-aligned trial.
First-half results show what public-company status costs. Operating expenses jumped as research on NS002 and the overhead of a listed Israeli issuer both scaled up, and the mid-year cash pile after the placement funds operations only into the second quarter of next year. Management still records substantial doubt about continuing as a going concern, because the same cash that covers a planned start and a first-quarter readout does not cover a commercial launch. The next year resolves whether the powder data hold in a registrational design and whether the company can raise the next tranche without crushing the residual claim.